219 related articles for article (PubMed ID: 34968032)
21. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
22. Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2.
Piossek C; Thierauch KH; Schneider-Mergener J; Volkmer-Engert R; Bachmann MF; Korff T; Augustin HG; Germeroth L
Thromb Haemost; 2003 Sep; 90(3):501-10. PubMed ID: 12958620
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
[TBL] [Abstract][Full Text] [Related]
24. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
26. Xiaotan Sanjie decoction inhibits angiogenesis in gastric cancer through Interleukin-8-linked regulation of the vascular endothelial growth factor pathway.
Shi J; Lu Y; Wei P
J Ethnopharmacol; 2016 Aug; 189():230-7. PubMed ID: 27224240
[TBL] [Abstract][Full Text] [Related]
27. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor (VEGF) inhibition--a critical review.
Moreira IS; Fernandes PA; Ramos MJ
Anticancer Agents Med Chem; 2007 Mar; 7(2):223-45. PubMed ID: 17348829
[TBL] [Abstract][Full Text] [Related]
29. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
[TBL] [Abstract][Full Text] [Related]
30. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
Siveen KS; Prabhu K; Krishnankutty R; Kuttikrishnan S; Tsakou M; Alali FQ; Dermime S; Mohammad RM; Uddin S
Curr Vasc Pharmacol; 2017; 15(4):339-351. PubMed ID: 28056756
[TBL] [Abstract][Full Text] [Related]
31. Anti-angiogenic effect of a chemically sulfated polysaccharide from Phellinus ribis by inhibiting VEGF/VEGFR pathway.
Ding J; Jia W; Cui Y; Jin J; Zhang Y; Xu L; Liu Y
Int J Biol Macromol; 2020 Jul; 154():72-81. PubMed ID: 32171839
[TBL] [Abstract][Full Text] [Related]
32. Sulfated Hyaluronan Alters Endothelial Cell Activation in Vitro by Controlling the Biological Activity of the Angiogenic Factors Vascular Endothelial Growth Factor-A and Tissue Inhibitor of Metalloproteinase-3.
Rother S; Samsonov SA; Moeller S; Schnabelrauch M; Rademann J; Blaszkiewicz J; Köhling S; Waltenberger J; Pisabarro MT; Scharnweber D; Hintze V
ACS Appl Mater Interfaces; 2017 Mar; 9(11):9539-9550. PubMed ID: 28248081
[TBL] [Abstract][Full Text] [Related]
33. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
Lohela M; Bry M; Tammela T; Alitalo K
Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
[TBL] [Abstract][Full Text] [Related]
34. A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated
Wang L; Xu M; Hu H; Zhang L; Ye F; Jin J; Fang H; Chen J; Chen G; Broussy S; Vidal M; Lv Z; Liu WQ
Front Pharmacol; 2021; 12():734544. PubMed ID: 34658874
[TBL] [Abstract][Full Text] [Related]
35. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors.
Verheul HM; Pinedo HM
Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S80-4. PubMed ID: 11970755
[TBL] [Abstract][Full Text] [Related]
36. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Bender RJ; Mac Gabhann F
BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
[TBL] [Abstract][Full Text] [Related]
37. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells.
Garvin S; Nilsson UW; Dabrosin C
Br J Cancer; 2005 Oct; 93(9):1005-10. PubMed ID: 16234819
[TBL] [Abstract][Full Text] [Related]
38. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.
Kay NE; Bone ND; Tschumper RC; Howell KH; Geyer SM; Dewald GW; Hanson CA; Jelinek DF
Leukemia; 2002 May; 16(5):911-9. PubMed ID: 11986954
[TBL] [Abstract][Full Text] [Related]
39. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Tammela T; Zarkada G; Wallgard E; Murtomäki A; Suchting S; Wirzenius M; Waltari M; Hellström M; Schomber T; Peltonen R; Freitas C; Duarte A; Isoniemi H; Laakkonen P; Christofori G; Ylä-Herttuala S; Shibuya M; Pytowski B; Eichmann A; Betsholtz C; Alitalo K
Nature; 2008 Jul; 454(7204):656-60. PubMed ID: 18594512
[TBL] [Abstract][Full Text] [Related]
40. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]